PANV, Inc., a biotechnology spun out of the Iwasaki Laboratory at Yale University, is developing pan-viral assets targeting diverse viruses. PANV antibodies specifically recognize unique host derived modifications on the surface of the viral particles bringing a revolutionary solution for permanently addressing multiple types of viral infections including Retroviruses, Influenza, Coronaviruses and Herpesviruses with a single therapeutic.